Trial · NCT02198794
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | SD-809 | Any TEAEs | 269 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | Part C: SD-809 | Any TEAEs | 23 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | SD-809 | Serious TEAEs | 68 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | Part C: SD-809 | Serious TEAEs | 5 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | SD-809 | Severe TEAEs | 57 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | Part C: SD-809 | Severe TEAEs | 3 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | SD-809 | Drug-Related TEAEs | 154 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | Part C: SD-809 | Drug-Related TEAEs | 3 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | SD-809 | TEAEs Leading to Withdrawal From Study | 42 | Participants | |
| Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal | Part C: SD-809 | TEAEs Leading to Withdrawal From Study | 3 | Participants | |
| Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating | Part B: Placebo | Pre-withdrawal | 5.7 | Standard Error 0.55 | units on a scale |
| Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating | Part B: SD-809 | Pre-withdrawal | 5.0 | Standard Error 0.49 | units on a scale |
| Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating | Part B: Placebo | Change at Post-withdrawal | 0.6 | Standard Error 0.28 | units on a scale |
| Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video Rating | Part B: SD-809 | Change at Post-withdrawal | 0 | Standard Error 0.29 | units on a scale |
| Part A: Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating | Part A: SD-809 | -6.6 | Standard Error 0.37 | units on a scale | |
| Part A: Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating | Part A: SD-809 | -6.3 | Standard Error 0.85 | units on a scale | |
| Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 145, as Assessed by the Site Rating | Part A: SD-809 | -57.0 | Standard Error 2.43 | percent change | |
| Part A: Percent Change From Baseline in Total Motor AIMS Score at Week 158, as Assessed by the Site Rating | Part A: SD-809 | -54.9 | Standard Error 6.76 | percent change | |
| Part A: Percentage of Participants Who Had a 50% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating | Part A: SD-809 | 67 | percentage of participants | ||
| Part A: Percentage of Participants Who Had a 70% or Greater Reduction From Baseline in Total Motor AIMS Score, as Assessed by the Site Rating | Part A: SD-809 | 42 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02198794/results